Cyclophosphamide (generic), Cytoxan Newswire (Page 2)

Cyclophosphamide (generic), Cytoxan Newswire (Page 2)

Comprehensive Real-Time News Feed for Cyclophosphamide (generic), Cytoxan. (Page 2)

Results 21 - 40 of 623 in Cyclophosphamide (generic), Cytoxan

  1. Zacks Investment Research Upgrades Baxter International (BAX) to HoldRead the original story w/Photo

    Friday Jan 5 | Daily Political

    According to Zacks, "Over the past year, Baxter has outperformed the broader industry in terms of price performance. The company's impressive performance at the hospital products and renal segments hold promise.

    Comment?

  2. Stem Cell Transplant Is Better Than Drug Therapy for SclerodermaRead the original story

    Thursday Jan 4 | Health News Digest

    Scleroderma with internal organ involvement is a debilitating and lethal autoimmune disorder with few effective treatments. But a study led by Duke Health researchers has found new cause for optimism using an aggressive stem cell transplant regimen.

    Comment?

  3. Investment Analysts' Upgrades for January, 4thRead the original story w/Photo

    Thursday Jan 4 | AmericanBankingNews.com

    According to Zacks, "Over the past year, Baxter has outperformed the broader industry in terms of price performance. The company's impressive performance at the hospital products and renal segments hold promise.

    Comment?

  4. Stem Cell Transplant Offers Hope for Immune Disorder SclerodermaRead the original story w/Photo

    Thursday Jan 4 | News Max

    A stem cell transplant works better than medicine to extend the lives of people with scleroderma, an autoimmune disease in which the skin hardens and organs break down, researchers said Wednesday. The findings in the New England Journal of Medicine point to a new way of treating the incurable disease, which affects some 2.5 million people worldwide, most of them women of childbearing age.

    Comment?

  5. Stem cell transplant for severe scleroderma improves survival, quality of lifeRead the original story

    Wednesday Jan 3 | PressReleasePoint

    New clinical trial findings show that a therapeutic regimen involving transplantation of a person's own blood-forming stem cells can improve survival and quality of life for people with severe scleroderma, a life-threatening autoimmune disease. The regimen, known as myeloablative autologous hematopoietic stem cell transplant , includes chemotherapy and total body radiation to destroy the bone marrow followed by transplantation of the person's own blood-forming stem cells to reconstitute the marrow and immune system.

    Comment?

  6. Stem cell transplant offers hope for scleroderma patientsRead the original story w/Photo

    Wednesday Jan 3 | Manila Bulletin

    A stem cell transplant works better than medicine to extend the lives of people with scleroderma, an autoimmune disease in which the skin hardens and organs break down, researchers said Wednesday. The findings in the New England Journal of Medicine point to a new way of treating the incurable disease, which affects some 2.5 million people worldwide, most of them women of childbearing age.

    Comment?

  7. Study Shows Stem Cell Transplant Is Better Than Drug Therapy for SclerodermaRead the original story w/Photo

    Wednesday Jan 3 | Newswise

    Scleroderma with internal organ involvement is a debilitating and lethal autoimmune disorder with few effective treatments. But a study led by Duke Health researchers has found new cause for optimism using an aggressive stem cell transplant regimen.

    Comment?

  8. Emerging Opportunities in Primary Systemic Amyloidosis Market with Current Trends AnalysisRead the original story w/Photo

    Friday Dec 29 | SBWire

    Amyloids are the substance made up of abnormally formed protein in the bone marrow that gets saturated in different tissues or organs of the body. The condition is termed as amyloidosis.

    Comment?

  9. The impact of intravenous methylprednisolone pulses on renal survival ...Read the original story w/Photo

    Thursday Dec 28 | BioMed Central

    High-dose methylprednisolone pulses were one of the main treatments for anti-neutrophil cytoplasmic autoantibody associated vasculitides but had obvious side effects. We aimed to know the impact on renal survival and identify the prognostic factors of this treatment in Chinese AAV patients with severe renal involvement.

    Comment?

  10. Baxter International (BAX) Rating Lowered to Hold at Zacks Investment ResearchRead the original story w/Photo

    Tuesday Dec 26 | AmericanBankingNews.com

    According to Zacks, "Over the past year, Baxter has outperformed the broader industry in terms of price performance.The company's impressive performance in the third quarter 2017 at the hospital products and renal segments hold promise. Baxter launched the oXIRIS set for continuous renal replacement therapy and sepsis management protocols in select markets of Europe, Middle East and Africa recently.

    Comment?

  11. Equities Research Analysts' Downgrades for December, 26th (AIG,...Read the original story w/Photo

    Tuesday Dec 26 | AmericanBankingNews.com

    According to Zacks, "American International Group's shares have underperformed the industry year to date. The company has been suffering from tough market conditions and its massive size with numerous uncorrelated businesses creating little or no synergy.

    Comment?

  12. Long-term Peripheral Neuropathy in Breast Cancer Patients Treated...Read the original story

    Dec 22, 2017 | CiteULike

    The long-term effects of chemotherapy are sparsely reported. Peripheral neuropathy is one of the most frequent toxicities associated with taxane use for the treatment of early-stage breast cancer.

    Comment?

  13. Rheumatoid factor is correlated with disease activity and...Read the original story w/Photo

    Dec 19, 2017 | BioMed Central

    Some patients with antineutrophil cytoplasmic antibody -associated vasculitis also have positivity of rheumatoid factor . However, the clinical significance of this occurrence remains unknown in AAV patients.

    Comment?

  14. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita.Read the original story

    Dec 19, 2017 | CiteULike

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , Vol. 19, No.

    Comment?

  15. Iovance Biotherapeutics'Read the original story w/Photo

    Dec 13, 2017 | Seeking Alpha

    Good morning everyone. My name is Dr. Maria Fardis, I'm the President & Chief Executive Officer at Iovance Biotherapeutics.

    Comment?

  16. Clinical trials in minimal change disease.Read the original story

    Dec 14, 2017 | CiteULike

    Minimal change disease is a pathological condition characterized by subtle glomerular lesions causing massive and reversible proteinuria that is usually steroid sensitive. Recurrence of symptoms of active disease following successful treatment and steroid toxicity requires the use of other drugs to attain or maintain remission.

    Comment?

  17. Alkylating Agents Market to Witness an Outstanding Growth by 2025Read the original story w/Photo

    Dec 11, 2017 | SBWire

    The organization also projected that the number of cancer cases could reach 22 million by 2032. Lung, liver, stomach, colorectal, and breast are among the leading cause of cancer deaths.

    Comment?

  18. Combination of chemotherapy and targeted drug improves response in younger CLL patientsRead the original story w/Photo

    Dec 11, 2017 | Medical News

    Among younger patients newly diagnosed with chronic lymphocytic leukemia , treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone, according to an investigator-initiated multi-center phase II clinical trial. "We're combining the most potent chemotherapy regimen with a highly active novel agent, trying to develop an optimal regimen for younger patients," said Matthew Davids, MD, MMSc, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, who reported on the study in an oral presentation at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta.

    Comment?

  19. Primary orbital Ewing sarcoma family of tumors: a study of 12 casesRead the original story

    Dec 8, 2017 | Eye

    Thank you for visiting nature.com. You are using a browser version with limited support for CSS.

    Comment?

  20. VDT Pace effective in relapsed, refractory multiple myelomaRead the original story w/Photo

    Dec 7, 2017 | PhysOrg Weblog

    For heavily pre-treated patients with relapsed/refractory multiple myeloma , bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide regimen and its modifications are effective, according to a study published online Oct. 25 in the American Journal of Hematology . Arjun Lakshman, M.D., from the Mayo Clinic in Rochester, Minn., and colleagues analyzed outcomes of 141 patients with RRMM who received VPLRs between 2006 and 2017.

    Comment?